1. 2F-3DPrint : D2.3 Structural analysis protocolLucija Hanžič, Luka Šadl, Rok Bregar, Miha Hren, 2026, projektna dokumentacija (idejni projekt, izvedbeni projekt) Ključne besede: concrete, additive manufacturing, mechanical resistance, laboratory testing, Eurocode 6, TMS 402 Objavljeno v DiRROS: 16.03.2026; Ogledov: 359; Prenosov: 0 Gradivo ima več datotek! Več... |
2. Laboratory testing of old bridge girders : preliminary resultsMaja Kreslin, Mirko Kosič, Aljoša Šajna, Andrej Anžlin, Doron Hekič, Vladimir Požonec, Petra Triller, 2025, objavljeni znanstveni prispevek na konferenci Povzetek: This paper presents key results on the laboratory testing of old girders removed from a flood-damaged bridge located near Ljubljana, Slovenia. The structure was widened in 1989 to accommodate pedestrians and cyclists by integrating prefabricated prestressed reinforced concrete T-girders. To assess the structural behaviour of the bridge, six girders were subjected to a rigorous testing program involving bending and shear tests in a laboratory setting. The tests were performed on girders with static lengths of 12.20 meters and 9.90 meters. The program aimed to evaluate the structural performance of the girders. Preliminary results indicate satisfactory structural behaviour of the prestressed T-girders under the applied loads, with insights into their performance under both bending and shear stresses. This study contributes valuable data for assessing the long-term behaviour of bridges. The outcomes are particularly relevant for optimising resource allocation in bridge rehabilitation projects and ensuring safety and functionality in transportation networks. Ključne besede: laboratory testing, prestressed girders, assessment, load test, operational modal analysis, damage, acoustic emission Objavljeno v DiRROS: 22.01.2026; Ogledov: 421; Prenosov: 264
Celotno besedilo (15,91 MB) Gradivo ima več datotek! Več... |
3. Multicenter evaluation of different anti-Xa assays and diluted Russell’s viper venom time in ex vivo plasma samples from patients treated with rivaroxaban or apixabanMojca Božič Mijovski, Alenka Mavri, Jovan P. Antovic, Rickard E. Malmström, Désirée Coen Herak, 2025, izvirni znanstveni članek Povzetek: Background/Objectives: Different anti-Xa assays are routinely used to evaluate the plasma concentrations of direct factor X inhibitors (DXIs) rivaroxaban and apixaban, despite a lack of data on assay equivalence. Information on assay performance is particularly important at clinical decision cut-offs, such as 50 ng/mL or 30 ng/mL. The aim of this study was to evaluate the equivalence of different anti-Xa assays with the reference LC-MS/MS method for measuring rivaroxaban and apixaban concentrations in a multicenter study. In addition, the usefulness of the dRVVT as a simple coagulation test for emergency situations was evaluated. Methods: We included 122 patients with atrial fibrillation. Trough and peak blood samples were collected from 60 patients treated with rivaroxaban and 62 patients treated with apixaban. Rivaroxaban and apixaban plasma levels were measured by LC–MS/MS. Different anti-Xa assays were used in three laboratories to evaluate equivalence. Results: The concentrations in the analyzed samples ranged from 2 to 781 ng/mL for rivaroxaban and 9 to 568 ng/mL for apixaban. Only one of the anti-Xa assays gave equivalent results to LC-MS/MS for rivaroxaban, and none for apixaban. All anti-Xa assays significantly underestimated apixaban concentration, with a proportional bias between 10% and 20%. A high correlation was found between DXI concentration and dRVVT clotting time, but dRVVT was not consistently prolonged at clinically relevant DXI concentrations in plasma. Conclusions: Only one of the anti-Xa assays showed equivalence with LC-MS/MS for rivaroxaban, and none for apixaban. Several anti-Xa assays provided reliable results for rivaroxaban in the range of clinically relevant cut-off values, but none for apixaban, which could expose patients to a higher risk of bleeding and urgently needs further clinical research. The dRVVT test was not sensitive enough for reliable detection of clinically relevant DXI plasma concentrations and therefore cannot replace the anti-Xa assay in emergency situations. Ključne besede: atrial fibrillation, rivaroxaban, apixaban, anti-Xa, laboratory methods Objavljeno v DiRROS: 05.01.2026; Ogledov: 600; Prenosov: 321
Celotno besedilo (7,32 MB) Gradivo ima več datotek! Več... |
4. Contribution of naturally durable wood to the circular economyKoichi Yamamoto, Tomoko Osawa, Ryu Noda, 2025, izvirni znanstveni članek Povzetek: Total wood demand is projected by the FAO to increase by 49% between 2020 and 2050, despite deteriorating supply conditions such as deforestation and degradation due to fire and biological damage to forests. Service life extension and reuse of wood can help to mitigate this projected gap between supply and demand. Common construction timber species with moderately durable heartwood include Scots pine, Douglas fir and Japanese cedar. However, this durability varies widely among clones, growing sites and within tree trunks. The selection and utilization of highly durable clones or individuals within these timber species could contribute to extending the service life of building and civil engineering structures that are at greater risk of biodegradation, such as building façades and landscape engineering applications. The authors would like to advance the discussi- on on measures to utilize this selected timber with higher durability, including maintenance strategies and the complementary use of treated timber within the circular economy. Ključne besede: circular economy, heartwood, natural durability, service life, carbon storage, laboratory decay test, standard Objavljeno v DiRROS: 30.12.2025; Ogledov: 830; Prenosov: 558
Celotno besedilo (1,32 MB) |
5. |
6. International survey on Phenylketonuria newborn screeningDomen Trampuž, Peter C. J. I. Schielen, Rolf H. Zetterström, Maurizio Scarpa, François Feillet, Viktor Kožich, Trine Tangeraas, Ana Drole Torkar, Matej Mlinarič, Daša Perko, Žiga Iztok Remec, Barbka Repič-Lampret, Tadej Battelino, Urh Grošelj, 2025, izvirni znanstveni članek Povzetek: ewborn screening for Phenylketonuria enables early detection and timely treatment with a phenylalanine-restricted diet to prevent severe neurological impairment. Although effective and in use for 60 years, screening, diagnostic, and treatment practices still vary widely across countries and centers. To evaluate the Phenylketonuria newborn screening practices internationally, we designed a survey with questions focusing on the laboratory aspect of the screening system. We analyzed 24 completed surveys from 23 countries. Most participants used the same sampling age range of 48–72 h; they used tandem mass spectrometry and commercial non-derivatized kits to measure phenylalanine (Phe), and had non-negative cut-off values (COV) set mostly at 120 µmol/L of Phe. Participants mostly used genetic analysis of blood and detailed amino acid analysis from blood plasma as their confirmatory methods and set the COV for the initiation of dietary therapy at 360 µmol/L of Phe. There were striking differences in practice as well. While most participants reported a 48–72 h range for age at sampling, that range was overall quite diverse Screening COV varied as well. Additional screening parameters, e.g., the phenylalanine/tyrosine ratio were used by some participants to determine the screening result. Some participants included testing for tetrahydrobiopterin deficiency, or galactosemia in their diagnostic process. Results together showed that there is room to select a best practice from the many practices applied. Such a best practice of PKU-NBS parameters and post-screening parameters could then serve as a generally applicable guideline. Ključne besede: phenylketonuria, newborn, neonatal, screening, international, survey, laboratory, methods, cut-off Objavljeno v DiRROS: 04.12.2025; Ogledov: 3797; Prenosov: 342
Celotno besedilo (912,91 KB) Gradivo ima več datotek! Več... |
7. A cross-sectional study of laboratory parameters 5–6 months after the first COVID-19 infectionTaja Zore, Jasna Lojk, Katarina Reberšek, Elizabeta Božnar Alič, Urška Čegovnik Primožič, Alenka France Štiglic, Aleš Jerin, Irena Prodan Žitnik, Helena Podgornik, Nada Snoj, Barbara Ostanek, Gabriele Turel, Tatjana Lejko-Zupanc, Janja Marc, Darko Černe, 2025, izvirni znanstveni članek Povzetek: Objectives: Despite extensive study of COVID-19 disease, only a few studies also addressed the aftermath of the disease and potential long-term consequences. The aim of this study was to assess COVID-19 resolution through the cross-sectional analysis of an extensive range of haematological and biochemical laboratory parameters and to find potential markers still associated with disease severity 5-6-months post infection.
Methods: In this study, we analysed 92 routine biochemical, haematological and immunological parameters in 75 non-vaccinated patients 5–6 months after recorded first time SARS-CoV-2 infection without reinfection. Demographic and disease severity data were obtained through surveys.
Results: The majority of analysed parameters were within the normal reference intervals, however, statistically significant correlations with the disease severity were detected in 15 parameters: B lymphocytes, NK cells, interleukin (IL)-12, IL-1β, cortisol, ferritin, SARS-CoV-2 specific IgG and IgM antibodies, Na, Cl, creatinine, alkaline phosphatase, cholesterol, HbA1c and alpha 2 and beta 2 globulin fractions of the proteinogram.
Conclusions: Although most observed parameters returned to their normal reference intervals, significant correlations were still observed with disease severity, that could indicate either the pre-infection baseline state which affected disease outcome or minor remaining alterations in function of certain organs, pertaining their stress or damage during the acute phase of the disease. Ključne besede: disease severity, laboratory parameters, resolution, COVID-19, SARS-CoV-2, laboratory diagnosis Objavljeno v DiRROS: 07.11.2025; Ogledov: 598; Prenosov: 283
Celotno besedilo (3,36 MB) Gradivo ima več datotek! Več... |
8. Mapping the path to excellence : Evaluation of the diagnostic and treatment tools for invasive fungal infections in the BalkansNikola Pantić, Aleksandra Barać, Vasilika Mano, Amela Dedeić-Ljubović, Ivan Malkodanski, Ozren Jaksić, Despoina Gkentzi, Mirjana Mitrović, Jelena Todorović, Oxana Munteanu, 2024, izvirni znanstveni članek Ključne besede: fungal infections, Balkans, laboratory capacity, antifungal treatment, diagnostic methods Objavljeno v DiRROS: 03.07.2025; Ogledov: 664; Prenosov: 457
Celotno besedilo (1,74 MB) Gradivo ima več datotek! Več... |
9. Epidemiological and clinical insights into enterovirus circulation in Europe, 2018 - 2023 : a multi-center retrospective surveillance studySten de Schrijver, Emiel Vanhulle, Anne Ingenbleek, Leonidas Alexakis, 2025, izvirni znanstveni članek Povzetek: Background Enteroviruses (EV) cause yearly outbreaks with severe infections, particularly in young children. This study investigates EV circulation, age, and clinical presentations in Europe from 2018 to 2023. Methods Aggregated data were requested from the European Centre for Disease Prevention and Control National Focal Points for Surveillance and European Non-Polio Enterovirus Network. Data included detection month, specimen type, age group, and clinical presentation for the 10 most commonly reported EV types per year. Results Twenty-eight institutions (16 countries) reported 563 654 EV tests during the study period with 33 265 (5.9%) EV positive. Forty-two types were identified (n = 11 605 cases) with echovirus 30 (E30), coxsackievirus A6 (CVA6), EV-D68, E9, E11, CVB5, E18, CVB4, EV-A71, and E6 most frequently reported. E30 declined after 2018/2019, while CVA6, CVB5, E9, E11, and EV-D68 were prevalent both before and after the coronavirus disease 2019 (COVID-19) pandemic, and CVB4 and E18 were prevalent after the pandemic. A shift in seasons (summer to fall) and specimen positivity (feces to respiratory) was observed. Neurological signs predominated among EV-A71, CVB4, CVB5, E6, E9, E11, E18, and E30 (30%–72%). CVB4, CVB5, E9, E11, and E18 were frequently reported among neonates (18%–32%). CVA6 was frequently associated with hand, foot and mouth disease, and EV-D68 with respiratory infections. Paralysis was reported among 22 infections, associated with 10 nonpolio types. Conclusions This study emphasizes the widespread circulation and severity of EV infections in Europe, as well as the (re)emergence of specific types postpandemic. Our findings highlight the need for continuous EV surveillance to monitor variation in circulation, age, and clinical presentations, including paralysis among nonpolio EV infections. Ključne besede: enterovirus, laboratory detection, surveillance, Europe, epidemiology Objavljeno v DiRROS: 27.06.2025; Ogledov: 919; Prenosov: 565
Celotno besedilo (1,06 MB) Gradivo ima več datotek! Več... |
10. From crisis to routine – standardization of SARS-CoV-2 genome detection by enhanced EQA schemes in a scientific pandemic networkMartin Kammel, Hans-Peter Grunert, Anika Zimmermann, Annemarie Martin, Vanessa Lindig, Mojca Milavec, 2025, izvirni znanstveni članek Povzetek: In the beginning of 2020, the outbreak of the COVID-19 pandemic led to a crisis in which diagnostic methods for the genome detection of SARS-CoV-2 were urgently needed. Based on the very early publication of the basic principles for a diagnostic test for the genome detection of SARS-CoV-2, the first noncommercial laboratory-developed tests (LDTs) and commercial tests were introduced. As there was considerable uncertainty about the reliability and performance of different tests and different laboratories, INSTAND established external quality assessment (EQA) schemes for the detection of SARS-CoV-2 starting in April 2020. In close partnership in a scientific network, the EQA schemes were enhanced, especially the April, June and November 2020 terms. The enhancement included: (i) immediate provision of suitable virus including variants of concern at the beginning of the pandemic outbreak, (ii) short frequency of EQA schemes, (iii) concentration dependency of the testing and sensitivity check, achieved by using SARS-CoV-2-positive samples from a 10-fold dilution series of the same starting material, (iv) specificity check of the testing, achieved by using SARS-CoV-2-negative samples containing human coronaviruses or MERS CoV, (v) revealed samples for orientation on test performance during an ongoing or at the start of an EQA scheme using a pre-quantified SARS-CoV-2-positive EQA sample with a low viral RNA load of only 1 570 copies/mL assigned by digital PCR (dPCR) in June 2020 and (vi) quantified reference materials based on the experiences of the first two EQA schemes with dPCR-assigned values in copies/mL beginning in November 2020 for self-evaluation of the applied test system. This manuscript summarizes the results of a total of 13 EQA schemes for the detection of SARS-CoV-2 between April 2020 and June 2023 in which a total of 1 413 laboratories from 49 countries participated. The qualitative results for the detection of SARS-CoV-2-positive samples were between 95.8 % and 99.7 % correct positive, excluding extremely low concentration samples. For all SARS-CoV-2-negative EQA samples, the qualitative success rates ranged from 95.1 % to 99.4 % correct negative results. The widely varying values for the cycle threshold (Ct)/crossing point (Cq) reported for the different target genes and test systems were striking. A few laboratories reported quantitative results in copies/mL for several VOCs with an acceptable rate of over 93 % correct positive results in the majority of cases. The description of the enhanced EQA schemes for SARS-CoV-2 detection in terms of timing and scope can serve as a blueprint for the rapid development of a quality assessment of diagnostics for an emerging pathogen. Ključne besede: COVID-19 pandemic, SARS-CoV-2, virus genome detection tests, reference materials, external quality assessment, laboratory medicine, epidemiology Objavljeno v DiRROS: 18.06.2025; Ogledov: 988; Prenosov: 742
Celotno besedilo (10,30 MB) Gradivo ima več datotek! Več... |